nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimozide—CYP1A2—Pentoxifylline—systemic scleroderma	0.0753	0.141	CbGbCtD
Pimozide—CYP1A2—Leflunomide—systemic scleroderma	0.0718	0.135	CbGbCtD
Pimozide—ABCB1—Lisinopril—systemic scleroderma	0.0658	0.123	CbGbCtD
Pimozide—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0596	0.112	CbGbCtD
Pimozide—ABCB1—Captopril—systemic scleroderma	0.0493	0.0923	CbGbCtD
Pimozide—CYP2D6—Captopril—systemic scleroderma	0.0464	0.087	CbGbCtD
Pimozide—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0388	0.0727	CbGbCtD
Pimozide—CYP2C19—Prednisone—systemic scleroderma	0.0384	0.072	CbGbCtD
Pimozide—ABCB1—Prednisone—systemic scleroderma	0.031	0.0581	CbGbCtD
Pimozide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0232	0.0435	CbGbCtD
Pimozide—CYP3A4—Prednisone—systemic scleroderma	0.0186	0.0348	CbGbCtD
Pimozide—ABCB1—Methotrexate—systemic scleroderma	0.0156	0.0291	CbGbCtD
Pimozide—HTR2A—myenteric nerve plexus—systemic scleroderma	0.00816	0.108	CbGeAlD
Pimozide—HTR2A—pulmonary artery—systemic scleroderma	0.00577	0.0764	CbGeAlD
Pimozide—CALM2—artery—systemic scleroderma	0.00353	0.0467	CbGeAlD
Pimozide—CALM1—artery—systemic scleroderma	0.00351	0.0465	CbGeAlD
Pimozide—CACNA1G—digestive system—systemic scleroderma	0.00311	0.0411	CbGeAlD
Pimozide—CALM2—endothelium—systemic scleroderma	0.00298	0.0394	CbGeAlD
Pimozide—CALM1—endothelium—systemic scleroderma	0.00297	0.0393	CbGeAlD
Pimozide—CALM2—blood vessel—systemic scleroderma	0.00275	0.0364	CbGeAlD
Pimozide—CALM1—blood vessel—systemic scleroderma	0.00274	0.0362	CbGeAlD
Pimozide—HTR2A—artery—systemic scleroderma	0.00214	0.0283	CbGeAlD
Pimozide—HTR2A—endothelium—systemic scleroderma	0.00181	0.0239	CbGeAlD
Pimozide—HTR2A—blood vessel—systemic scleroderma	0.00167	0.0221	CbGeAlD
Pimozide—CALM3—smooth muscle tissue—systemic scleroderma	0.00164	0.0217	CbGeAlD
Pimozide—CALM2—connective tissue—systemic scleroderma	0.00141	0.0186	CbGeAlD
Pimozide—CALM1—connective tissue—systemic scleroderma	0.0014	0.0186	CbGeAlD
Pimozide—CALM2—smooth muscle tissue—systemic scleroderma	0.00129	0.0171	CbGeAlD
Pimozide—CALM1—smooth muscle tissue—systemic scleroderma	0.00128	0.017	CbGeAlD
Pimozide—CALM2—skin of body—systemic scleroderma	0.00127	0.0168	CbGeAlD
Pimozide—CALM1—skin of body—systemic scleroderma	0.00127	0.0168	CbGeAlD
Pimozide—CALM3—tendon—systemic scleroderma	0.00123	0.0163	CbGeAlD
Pimozide—ABCB1—blood vessel—systemic scleroderma	0.00109	0.0145	CbGeAlD
Pimozide—CALM3—lung—systemic scleroderma	0.00108	0.0143	CbGeAlD
Pimozide—HRH1—connective tissue—systemic scleroderma	0.00102	0.0135	CbGeAlD
Pimozide—CALM2—digestive system—systemic scleroderma	0.00102	0.0135	CbGeAlD
Pimozide—CALM1—digestive system—systemic scleroderma	0.00101	0.0134	CbGeAlD
Pimozide—CALM2—tendon—systemic scleroderma	0.000969	0.0128	CbGeAlD
Pimozide—CYP2C19—digestive system—systemic scleroderma	0.000967	0.0128	CbGeAlD
Pimozide—CALM1—tendon—systemic scleroderma	0.000965	0.0128	CbGeAlD
Pimozide—HRH1—smooth muscle tissue—systemic scleroderma	0.000936	0.0124	CbGeAlD
Pimozide—HTR2A—connective tissue—systemic scleroderma	0.000855	0.0113	CbGeAlD
Pimozide—CALM2—lung—systemic scleroderma	0.000851	0.0112	CbGeAlD
Pimozide—CALM1—lung—systemic scleroderma	0.000847	0.0112	CbGeAlD
Pimozide—CYP1A2—digestive system—systemic scleroderma	0.00079	0.0104	CbGeAlD
Pimozide—HTR2A—smooth muscle tissue—systemic scleroderma	0.000782	0.0103	CbGeAlD
Pimozide—DRD2—lung—systemic scleroderma	0.000782	0.0103	CbGeAlD
Pimozide—CYP3A5—digestive system—systemic scleroderma	0.000762	0.0101	CbGeAlD
Pimozide—HRH1—digestive system—systemic scleroderma	0.000739	0.00978	CbGeAlD
Pimozide—CYP2E1—digestive system—systemic scleroderma	0.000711	0.0094	CbGeAlD
Pimozide—HRH1—tendon—systemic scleroderma	0.000704	0.00931	CbGeAlD
Pimozide—CYP2E1—tendon—systemic scleroderma	0.000676	0.00894	CbGeAlD
Pimozide—Agitation—Mycophenolic acid—systemic scleroderma	0.000667	0.00195	CcSEcCtD
Pimozide—Gynaecomastia—Methotrexate—systemic scleroderma	0.000664	0.00195	CcSEcCtD
Pimozide—CYP1A2—lung—systemic scleroderma	0.00066	0.00872	CbGeAlD
Pimozide—Mental disorder—Lisinopril—systemic scleroderma	0.000658	0.00193	CcSEcCtD
Pimozide—Dizziness—Pentoxifylline—systemic scleroderma	0.000658	0.00193	CcSEcCtD
Pimozide—Hypertension—Leflunomide—systemic scleroderma	0.000657	0.00192	CcSEcCtD
Pimozide—Decreased appetite—Captopril—systemic scleroderma	0.000655	0.00192	CcSEcCtD
Pimozide—Syncope—Mycophenolic acid—systemic scleroderma	0.000651	0.00191	CcSEcCtD
Pimozide—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00065	0.0019	CcSEcCtD
Pimozide—Myalgia—Leflunomide—systemic scleroderma	0.000648	0.0019	CcSEcCtD
Pimozide—Chest pain—Leflunomide—systemic scleroderma	0.000648	0.0019	CcSEcCtD
Pimozide—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000647	0.00189	CcSEcCtD
Pimozide—Constipation—Captopril—systemic scleroderma	0.000644	0.00189	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000643	0.00188	CcSEcCtD
Pimozide—Palpitations—Mycophenolic acid—systemic scleroderma	0.000642	0.00188	CcSEcCtD
Pimozide—Skin disorder—Azathioprine—systemic scleroderma	0.000639	0.00187	CcSEcCtD
Pimozide—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000638	0.00187	CcSEcCtD
Pimozide—CYP3A5—lung—systemic scleroderma	0.000636	0.00841	CbGeAlD
Pimozide—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000634	0.00186	CcSEcCtD
Pimozide—Dry mouth—Leflunomide—systemic scleroderma	0.000634	0.00186	CcSEcCtD
Pimozide—Vomiting—Pentoxifylline—systemic scleroderma	0.000632	0.00185	CcSEcCtD
Pimozide—Convulsion—Mycophenolic acid—systemic scleroderma	0.000629	0.00184	CcSEcCtD
Pimozide—Muscle spasms—Lisinopril—systemic scleroderma	0.000629	0.00184	CcSEcCtD
Pimozide—Rash—Pentoxifylline—systemic scleroderma	0.000627	0.00184	CcSEcCtD
Pimozide—Hypertension—Mycophenolic acid—systemic scleroderma	0.000627	0.00184	CcSEcCtD
Pimozide—Dermatitis—Pentoxifylline—systemic scleroderma	0.000626	0.00183	CcSEcCtD
Pimozide—Headache—Pentoxifylline—systemic scleroderma	0.000623	0.00182	CcSEcCtD
Pimozide—Chest pain—Mycophenolic acid—systemic scleroderma	0.000618	0.00181	CcSEcCtD
Pimozide—Myalgia—Mycophenolic acid—systemic scleroderma	0.000618	0.00181	CcSEcCtD
Pimozide—HTR2A—digestive system—systemic scleroderma	0.000618	0.00817	CbGeAlD
Pimozide—HRH1—lung—systemic scleroderma	0.000618	0.00817	CbGeAlD
Pimozide—Vision blurred—Lisinopril—systemic scleroderma	0.000616	0.0018	CcSEcCtD
Pimozide—Asthenia—Mometasone—systemic scleroderma	0.000616	0.0018	CcSEcCtD
Pimozide—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000615	0.0018	CcSEcCtD
Pimozide—Hypotension—Azathioprine—systemic scleroderma	0.000615	0.0018	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000614	0.0018	CcSEcCtD
Pimozide—Tremor—Lisinopril—systemic scleroderma	0.000613	0.00179	CcSEcCtD
Pimozide—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000611	0.00179	CcSEcCtD
Pimozide—Nervous system disorder—Leflunomide—systemic scleroderma	0.000609	0.00178	CcSEcCtD
Pimozide—Pruritus—Mometasone—systemic scleroderma	0.000607	0.00178	CcSEcCtD
Pimozide—Tachycardia—Leflunomide—systemic scleroderma	0.000606	0.00177	CcSEcCtD
Pimozide—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000605	0.00177	CcSEcCtD
Pimozide—Anaemia—Lisinopril—systemic scleroderma	0.000604	0.00177	CcSEcCtD
Pimozide—Skin disorder—Leflunomide—systemic scleroderma	0.000603	0.00177	CcSEcCtD
Pimozide—Hyperhidrosis—Leflunomide—systemic scleroderma	0.0006	0.00176	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000599	0.00175	CcSEcCtD
Pimozide—CYP2E1—lung—systemic scleroderma	0.000593	0.00785	CbGeAlD
Pimozide—Anorexia—Leflunomide—systemic scleroderma	0.000592	0.00173	CcSEcCtD
Pimozide—Nausea—Pentoxifylline—systemic scleroderma	0.000591	0.00173	CcSEcCtD
Pimozide—HTR2A—tendon—systemic scleroderma	0.000588	0.00777	CbGeAlD
Pimozide—Diarrhoea—Mometasone—systemic scleroderma	0.000587	0.00172	CcSEcCtD
Pimozide—Syncope—Lisinopril—systemic scleroderma	0.000586	0.00172	CcSEcCtD
Pimozide—Leukopenia—Lisinopril—systemic scleroderma	0.000585	0.00171	CcSEcCtD
Pimozide—Shock—Mycophenolic acid—systemic scleroderma	0.000583	0.00171	CcSEcCtD
Pimozide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000581	0.0017	CcSEcCtD
Pimozide—Hypotension—Leflunomide—systemic scleroderma	0.00058	0.0017	CcSEcCtD
Pimozide—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000578	0.00169	CcSEcCtD
Pimozide—Palpitations—Lisinopril—systemic scleroderma	0.000578	0.00169	CcSEcCtD
Pimozide—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000577	0.00169	CcSEcCtD
Pimozide—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000576	0.00169	CcSEcCtD
Pimozide—Loss of consciousness—Lisinopril—systemic scleroderma	0.000575	0.00168	CcSEcCtD
Pimozide—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000573	0.00168	CcSEcCtD
Pimozide—CYP3A4—digestive system—systemic scleroderma	0.000572	0.00756	CbGeAlD
Pimozide—Visual disturbance—Methotrexate—systemic scleroderma	0.000569	0.00167	CcSEcCtD
Pimozide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000568	0.00166	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000566	0.00166	CcSEcCtD
Pimozide—Anorexia—Mycophenolic acid—systemic scleroderma	0.000565	0.00165	CcSEcCtD
Pimozide—CYP2D6—digestive system—systemic scleroderma	0.000563	0.00744	CbGeAlD
Pimozide—Insomnia—Leflunomide—systemic scleroderma	0.000562	0.00164	CcSEcCtD
Pimozide—Myalgia—Lisinopril—systemic scleroderma	0.000557	0.00163	CcSEcCtD
Pimozide—Chest pain—Lisinopril—systemic scleroderma	0.000557	0.00163	CcSEcCtD
Pimozide—Hypotension—Mycophenolic acid—systemic scleroderma	0.000554	0.00162	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000553	0.00162	CcSEcCtD
Pimozide—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000551	0.00161	CcSEcCtD
Pimozide—Vomiting—Mometasone—systemic scleroderma	0.000546	0.0016	CcSEcCtD
Pimozide—Dry mouth—Lisinopril—systemic scleroderma	0.000545	0.00159	CcSEcCtD
Pimozide—Rash—Mometasone—systemic scleroderma	0.000541	0.00158	CcSEcCtD
Pimozide—Asthenia—Captopril—systemic scleroderma	0.000541	0.00158	CcSEcCtD
Pimozide—Dermatitis—Mometasone—systemic scleroderma	0.000541	0.00158	CcSEcCtD
Pimozide—Decreased appetite—Leflunomide—systemic scleroderma	0.00054	0.00158	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00054	0.00158	CcSEcCtD
Pimozide—Headache—Mometasone—systemic scleroderma	0.000538	0.00157	CcSEcCtD
Pimozide—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000537	0.00157	CcSEcCtD
Pimozide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000536	0.00157	CcSEcCtD
Pimozide—Insomnia—Mycophenolic acid—systemic scleroderma	0.000536	0.00157	CcSEcCtD
Pimozide—Pruritus—Captopril—systemic scleroderma	0.000533	0.00156	CcSEcCtD
Pimozide—Constipation—Leflunomide—systemic scleroderma	0.000531	0.00156	CcSEcCtD
Pimozide—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00053	0.00155	CcSEcCtD
Pimozide—Somnolence—Mycophenolic acid—systemic scleroderma	0.000527	0.00154	CcSEcCtD
Pimozide—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000527	0.00154	CcSEcCtD
Pimozide—Shock—Lisinopril—systemic scleroderma	0.000525	0.00154	CcSEcCtD
Pimozide—Tachycardia—Lisinopril—systemic scleroderma	0.000521	0.00153	CcSEcCtD
Pimozide—Skin disorder—Lisinopril—systemic scleroderma	0.000518	0.00152	CcSEcCtD
Pimozide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000516	0.00151	CcSEcCtD
Pimozide—HTR2A—lung—systemic scleroderma	0.000516	0.00682	CbGeAlD
Pimozide—Diarrhoea—Captopril—systemic scleroderma	0.000516	0.00151	CcSEcCtD
Pimozide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000515	0.00151	CcSEcCtD
Pimozide—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000514	0.0015	CcSEcCtD
Pimozide—Erectile dysfunction—Prednisone—systemic scleroderma	0.000513	0.0015	CcSEcCtD
Pimozide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000513	0.0015	CcSEcCtD
Pimozide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000512	0.0015	CcSEcCtD
Pimozide—Nausea—Mometasone—systemic scleroderma	0.00051	0.00149	CcSEcCtD
Pimozide—Anorexia—Lisinopril—systemic scleroderma	0.000509	0.00149	CcSEcCtD
Pimozide—Weight increased—Prednisone—systemic scleroderma	0.000507	0.00149	CcSEcCtD
Pimozide—Constipation—Mycophenolic acid—systemic scleroderma	0.000507	0.00148	CcSEcCtD
Pimozide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000506	0.00148	CcSEcCtD
Pimozide—Weight decreased—Prednisone—systemic scleroderma	0.000504	0.00148	CcSEcCtD
Pimozide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000504	0.00147	CcSEcCtD
Pimozide—Hypotension—Lisinopril—systemic scleroderma	0.000499	0.00146	CcSEcCtD
Pimozide—Dizziness—Captopril—systemic scleroderma	0.000498	0.00146	CcSEcCtD
Pimozide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000496	0.00145	CcSEcCtD
Pimozide—Depression—Prednisone—systemic scleroderma	0.000496	0.00145	CcSEcCtD
Pimozide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000495	0.00145	CcSEcCtD
Pimozide—Urticaria—Leflunomide—systemic scleroderma	0.000493	0.00144	CcSEcCtD
Pimozide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000488	0.00143	CcSEcCtD
Pimozide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000488	0.00143	CcSEcCtD
Pimozide—Breast disorder—Methotrexate—systemic scleroderma	0.000487	0.00143	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000486	0.00142	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000484	0.00142	CcSEcCtD
Pimozide—Insomnia—Lisinopril—systemic scleroderma	0.000483	0.00141	CcSEcCtD
Pimozide—Vomiting—Captopril—systemic scleroderma	0.000479	0.0014	CcSEcCtD
Pimozide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000477	0.0014	CcSEcCtD
Pimozide—Rash—Captopril—systemic scleroderma	0.000475	0.00139	CcSEcCtD
Pimozide—Dermatitis—Captopril—systemic scleroderma	0.000475	0.00139	CcSEcCtD
Pimozide—Somnolence—Lisinopril—systemic scleroderma	0.000474	0.00139	CcSEcCtD
Pimozide—Headache—Captopril—systemic scleroderma	0.000472	0.00138	CcSEcCtD
Pimozide—Decreased appetite—Lisinopril—systemic scleroderma	0.000464	0.00136	CcSEcCtD
Pimozide—Eosinophilia—Methotrexate—systemic scleroderma	0.000461	0.00135	CcSEcCtD
Pimozide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000461	0.00135	CcSEcCtD
Pimozide—Shock—Mycophenolate mofetil—systemic scleroderma	0.00046	0.00135	CcSEcCtD
Pimozide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00134	CcSEcCtD
Pimozide—Constipation—Lisinopril—systemic scleroderma	0.000456	0.00134	CcSEcCtD
Pimozide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000456	0.00134	CcSEcCtD
Pimozide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000454	0.00133	CcSEcCtD
Pimozide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000452	0.00132	CcSEcCtD
Pimozide—Diarrhoea—Azathioprine—systemic scleroderma	0.00045	0.00132	CcSEcCtD
Pimozide—Nausea—Captopril—systemic scleroderma	0.000448	0.00131	CcSEcCtD
Pimozide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000447	0.00131	CcSEcCtD
Pimozide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000446	0.00131	CcSEcCtD
Pimozide—Asthenia—Leflunomide—systemic scleroderma	0.000446	0.0013	CcSEcCtD
Pimozide—Pancytopenia—Methotrexate—systemic scleroderma	0.000442	0.0013	CcSEcCtD
Pimozide—Pruritus—Leflunomide—systemic scleroderma	0.000439	0.00129	CcSEcCtD
Pimozide—Connective tissue disorder—Prednisone—systemic scleroderma	0.000438	0.00128	CcSEcCtD
Pimozide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000437	0.00128	CcSEcCtD
Pimozide—Dizziness—Azathioprine—systemic scleroderma	0.000435	0.00127	CcSEcCtD
Pimozide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000429	0.00126	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000426	0.00125	CcSEcCtD
Pimozide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000425	0.00124	CcSEcCtD
Pimozide—Diarrhoea—Leflunomide—systemic scleroderma	0.000425	0.00124	CcSEcCtD
Pimozide—Urticaria—Lisinopril—systemic scleroderma	0.000424	0.00124	CcSEcCtD
Pimozide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000423	0.00124	CcSEcCtD
Pimozide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000419	0.00123	CcSEcCtD
Pimozide—Vomiting—Azathioprine—systemic scleroderma	0.000418	0.00122	CcSEcCtD
Pimozide—Eye disorder—Prednisone—systemic scleroderma	0.000417	0.00122	CcSEcCtD
Pimozide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000416	0.00122	CcSEcCtD
Pimozide—Drowsiness—Methotrexate—systemic scleroderma	0.000415	0.00122	CcSEcCtD
Pimozide—Rash—Azathioprine—systemic scleroderma	0.000415	0.00121	CcSEcCtD
Pimozide—Dermatitis—Azathioprine—systemic scleroderma	0.000414	0.00121	CcSEcCtD
Pimozide—Depression—Methotrexate—systemic scleroderma	0.000414	0.00121	CcSEcCtD
Pimozide—Headache—Azathioprine—systemic scleroderma	0.000412	0.00121	CcSEcCtD
Pimozide—Dizziness—Leflunomide—systemic scleroderma	0.000411	0.0012	CcSEcCtD
Pimozide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000407	0.00119	CcSEcCtD
Pimozide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000405	0.00119	CcSEcCtD
Pimozide—ABCB1—digestive system—systemic scleroderma	0.000405	0.00535	CbGeAlD
Pimozide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000404	0.00118	CcSEcCtD
Pimozide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.0004	0.00117	CcSEcCtD
Pimozide—Sweating—Methotrexate—systemic scleroderma	0.000398	0.00117	CcSEcCtD
Pimozide—Vomiting—Leflunomide—systemic scleroderma	0.000395	0.00116	CcSEcCtD
Pimozide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000392	0.00115	CcSEcCtD
Pimozide—Rash—Leflunomide—systemic scleroderma	0.000392	0.00115	CcSEcCtD
Pimozide—Dermatitis—Leflunomide—systemic scleroderma	0.000391	0.00115	CcSEcCtD
Pimozide—Mental disorder—Prednisone—systemic scleroderma	0.000391	0.00114	CcSEcCtD
Pimozide—Nausea—Azathioprine—systemic scleroderma	0.000391	0.00114	CcSEcCtD
Pimozide—Headache—Leflunomide—systemic scleroderma	0.000389	0.00114	CcSEcCtD
Pimozide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000388	0.00113	CcSEcCtD
Pimozide—Asthenia—Lisinopril—systemic scleroderma	0.000383	0.00112	CcSEcCtD
Pimozide—Pruritus—Lisinopril—systemic scleroderma	0.000378	0.00111	CcSEcCtD
Pimozide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000377	0.0011	CcSEcCtD
Pimozide—Rash—Mycophenolic acid—systemic scleroderma	0.000374	0.00109	CcSEcCtD
Pimozide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000373	0.00109	CcSEcCtD
Pimozide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000371	0.00109	CcSEcCtD
Pimozide—Headache—Mycophenolic acid—systemic scleroderma	0.000371	0.00109	CcSEcCtD
Pimozide—Nausea—Leflunomide—systemic scleroderma	0.000369	0.00108	CcSEcCtD
Pimozide—Vision blurred—Prednisone—systemic scleroderma	0.000366	0.00107	CcSEcCtD
Pimozide—Diarrhoea—Lisinopril—systemic scleroderma	0.000365	0.00107	CcSEcCtD
Pimozide—Visual impairment—Methotrexate—systemic scleroderma	0.000359	0.00105	CcSEcCtD
Pimozide—Anaemia—Prednisone—systemic scleroderma	0.000359	0.00105	CcSEcCtD
Pimozide—Agitation—Prednisone—systemic scleroderma	0.000357	0.00105	CcSEcCtD
Pimozide—Dizziness—Lisinopril—systemic scleroderma	0.000353	0.00103	CcSEcCtD
Pimozide—Nausea—Mycophenolic acid—systemic scleroderma	0.000352	0.00103	CcSEcCtD
Pimozide—Eye disorder—Methotrexate—systemic scleroderma	0.000348	0.00102	CcSEcCtD
Pimozide—Syncope—Prednisone—systemic scleroderma	0.000348	0.00102	CcSEcCtD
Pimozide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000346	0.00101	CcSEcCtD
Pimozide—Loss of consciousness—Prednisone—systemic scleroderma	0.000341	0.000999	CcSEcCtD
Pimozide—Vomiting—Lisinopril—systemic scleroderma	0.000339	0.000994	CcSEcCtD
Pimozide—ABCB1—lung—systemic scleroderma	0.000338	0.00447	CbGeAlD
Pimozide—Rash—Lisinopril—systemic scleroderma	0.000337	0.000985	CcSEcCtD
Pimozide—Convulsion—Prednisone—systemic scleroderma	0.000337	0.000985	CcSEcCtD
Pimozide—Dermatitis—Lisinopril—systemic scleroderma	0.000336	0.000984	CcSEcCtD
Pimozide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000982	CcSEcCtD
Pimozide—Hypertension—Prednisone—systemic scleroderma	0.000335	0.000982	CcSEcCtD
Pimozide—Headache—Lisinopril—systemic scleroderma	0.000334	0.000979	CcSEcCtD
Pimozide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000969	CcSEcCtD
Pimozide—Myalgia—Prednisone—systemic scleroderma	0.000331	0.000968	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000328	0.000961	CcSEcCtD
Pimozide—Mental disorder—Methotrexate—systemic scleroderma	0.000327	0.000956	CcSEcCtD
Pimozide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00032	0.000937	CcSEcCtD
Pimozide—Nausea—Lisinopril—systemic scleroderma	0.000317	0.000928	CcSEcCtD
Pimozide—Shock—Prednisone—systemic scleroderma	0.000312	0.000913	CcSEcCtD
Pimozide—Nervous system disorder—Prednisone—systemic scleroderma	0.000311	0.00091	CcSEcCtD
Pimozide—Tachycardia—Prednisone—systemic scleroderma	0.000309	0.000906	CcSEcCtD
Pimozide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000309	0.000905	CcSEcCtD
Pimozide—Skin disorder—Prednisone—systemic scleroderma	0.000308	0.000901	CcSEcCtD
Pimozide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000306	0.000897	CcSEcCtD
Pimozide—Vision blurred—Methotrexate—systemic scleroderma	0.000306	0.000896	CcSEcCtD
Pimozide—Anorexia—Prednisone—systemic scleroderma	0.000302	0.000885	CcSEcCtD
Pimozide—Anaemia—Methotrexate—systemic scleroderma	0.0003	0.000878	CcSEcCtD
Pimozide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000297	0.000871	CcSEcCtD
Pimozide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000295	0.000863	CcSEcCtD
Pimozide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000295	0.000862	CcSEcCtD
Pimozide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000293	0.000858	CcSEcCtD
Pimozide—Leukopenia—Methotrexate—systemic scleroderma	0.000291	0.000851	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000289	0.000846	CcSEcCtD
Pimozide—Insomnia—Prednisone—systemic scleroderma	0.000287	0.000839	CcSEcCtD
Pimozide—Convulsion—Methotrexate—systemic scleroderma	0.000281	0.000823	CcSEcCtD
Pimozide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000278	0.000813	CcSEcCtD
Pimozide—Chest pain—Methotrexate—systemic scleroderma	0.000276	0.000809	CcSEcCtD
Pimozide—Myalgia—Methotrexate—systemic scleroderma	0.000276	0.000809	CcSEcCtD
Pimozide—Decreased appetite—Prednisone—systemic scleroderma	0.000276	0.000807	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000274	0.000804	CcSEcCtD
Pimozide—Constipation—Prednisone—systemic scleroderma	0.000271	0.000794	CcSEcCtD
Pimozide—Nervous system disorder—Methotrexate—systemic scleroderma	0.00026	0.000761	CcSEcCtD
Pimozide—Skin disorder—Methotrexate—systemic scleroderma	0.000257	0.000753	CcSEcCtD
Pimozide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000256	0.00075	CcSEcCtD
Pimozide—Anorexia—Methotrexate—systemic scleroderma	0.000253	0.000739	CcSEcCtD
Pimozide—Urticaria—Prednisone—systemic scleroderma	0.000252	0.000737	CcSEcCtD
Pimozide—Hypotension—Methotrexate—systemic scleroderma	0.000248	0.000725	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000241	0.000707	CcSEcCtD
Pimozide—Insomnia—Methotrexate—systemic scleroderma	0.00024	0.000702	CcSEcCtD
Pimozide—Somnolence—Methotrexate—systemic scleroderma	0.000236	0.00069	CcSEcCtD
Pimozide—Decreased appetite—Methotrexate—systemic scleroderma	0.00023	0.000674	CcSEcCtD
Pimozide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000229	0.00067	CcSEcCtD
Pimozide—Asthenia—Prednisone—systemic scleroderma	0.000227	0.000666	CcSEcCtD
Pimozide—Pruritus—Prednisone—systemic scleroderma	0.000224	0.000657	CcSEcCtD
Pimozide—Diarrhoea—Prednisone—systemic scleroderma	0.000217	0.000635	CcSEcCtD
Pimozide—Urticaria—Methotrexate—systemic scleroderma	0.00021	0.000616	CcSEcCtD
Pimozide—Dizziness—Prednisone—systemic scleroderma	0.00021	0.000614	CcSEcCtD
Pimozide—Vomiting—Prednisone—systemic scleroderma	0.000202	0.00059	CcSEcCtD
Pimozide—Rash—Prednisone—systemic scleroderma	0.0002	0.000585	CcSEcCtD
Pimozide—Dermatitis—Prednisone—systemic scleroderma	0.0002	0.000585	CcSEcCtD
Pimozide—Headache—Prednisone—systemic scleroderma	0.000199	0.000581	CcSEcCtD
Pimozide—Asthenia—Methotrexate—systemic scleroderma	0.00019	0.000557	CcSEcCtD
Pimozide—Nausea—Prednisone—systemic scleroderma	0.000188	0.000551	CcSEcCtD
Pimozide—Pruritus—Methotrexate—systemic scleroderma	0.000187	0.000549	CcSEcCtD
Pimozide—Diarrhoea—Methotrexate—systemic scleroderma	0.000181	0.000531	CcSEcCtD
Pimozide—Dizziness—Methotrexate—systemic scleroderma	0.000175	0.000513	CcSEcCtD
Pimozide—Vomiting—Methotrexate—systemic scleroderma	0.000168	0.000493	CcSEcCtD
Pimozide—Rash—Methotrexate—systemic scleroderma	0.000167	0.000489	CcSEcCtD
Pimozide—Dermatitis—Methotrexate—systemic scleroderma	0.000167	0.000489	CcSEcCtD
Pimozide—Headache—Methotrexate—systemic scleroderma	0.000166	0.000486	CcSEcCtD
Pimozide—Nausea—Methotrexate—systemic scleroderma	0.000157	0.000461	CcSEcCtD
Pimozide—OPRK1—Signaling Pathways—CSK—systemic scleroderma	4.19e-05	0.000857	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—CSK—systemic scleroderma	4.13e-05	0.000845	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—RHOB—systemic scleroderma	4.08e-05	0.000833	CbGpPWpGaD
Pimozide—CALM3—Disease—TGFBI—systemic scleroderma	4.07e-05	0.000831	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—CTLA4—systemic scleroderma	3.99e-05	0.000815	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—EDN1—systemic scleroderma	3.98e-05	0.000813	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—RHOB—systemic scleroderma	3.95e-05	0.000806	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—RHOB—systemic scleroderma	3.95e-05	0.000806	CbGpPWpGaD
Pimozide—CALM1—Disease—TGFBI—systemic scleroderma	3.94e-05	0.000804	CbGpPWpGaD
Pimozide—CALM2—Disease—TGFBI—systemic scleroderma	3.94e-05	0.000804	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—EDN1—systemic scleroderma	3.92e-05	0.000802	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—RHOB—systemic scleroderma	3.89e-05	0.000795	CbGpPWpGaD
Pimozide—HTR1A—GPCR ligand binding—CCL2—systemic scleroderma	3.87e-05	0.00079	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—CTLA4—systemic scleroderma	3.86e-05	0.000788	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—CTLA4—systemic scleroderma	3.86e-05	0.000788	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—RHOB—systemic scleroderma	3.85e-05	0.000788	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—SMAD7—systemic scleroderma	3.81e-05	0.000779	CbGpPWpGaD
Pimozide—CYP3A7—Metabolism—HSPG2—systemic scleroderma	3.78e-05	0.000771	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—SMAD7—systemic scleroderma	3.75e-05	0.000767	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—SMAD7—systemic scleroderma	3.74e-05	0.000765	CbGpPWpGaD
Pimozide—OPRM1—GPCR downstream signaling—EDN1—systemic scleroderma	3.7e-05	0.000757	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.69e-05	0.000754	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—SMAD7—systemic scleroderma	3.68e-05	0.000753	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—HSPG2—systemic scleroderma	3.67e-05	0.00075	CbGpPWpGaD
Pimozide—DRD3—GPCR downstream signaling—EDN1—systemic scleroderma	3.67e-05	0.00075	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—HSPG2—systemic scleroderma	3.64e-05	0.000743	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.59e-05	0.000734	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—CSK—systemic scleroderma	3.55e-05	0.000724	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—CSK—systemic scleroderma	3.51e-05	0.000717	CbGpPWpGaD
Pimozide—DRD2—GPCR ligand binding—CCL2—systemic scleroderma	3.4e-05	0.000694	CbGpPWpGaD
Pimozide—CALM3—Immune System—CSK—systemic scleroderma	3.39e-05	0.000693	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—EDN1—systemic scleroderma	3.36e-05	0.000687	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—RHOB—systemic scleroderma	3.36e-05	0.000686	CbGpPWpGaD
Pimozide—HTR2A—GPCR ligand binding—CCL2—systemic scleroderma	3.34e-05	0.000683	CbGpPWpGaD
Pimozide—CALM3—Immune System—IRF5—systemic scleroderma	3.34e-05	0.000682	CbGpPWpGaD
Pimozide—HRH1—GPCR ligand binding—CCL2—systemic scleroderma	3.33e-05	0.000681	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—EDN1—systemic scleroderma	3.33e-05	0.000681	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.28e-05	0.000671	CbGpPWpGaD
Pimozide—CALM1—Immune System—CSK—systemic scleroderma	3.28e-05	0.000671	CbGpPWpGaD
Pimozide—CALM2—Immune System—CSK—systemic scleroderma	3.28e-05	0.000671	CbGpPWpGaD
Pimozide—CHRM2—GPCR ligand binding—CCL2—systemic scleroderma	3.28e-05	0.00067	CbGpPWpGaD
Pimozide—CALM3—Disease—HSPG2—systemic scleroderma	3.24e-05	0.000663	CbGpPWpGaD
Pimozide—CALM2—Immune System—IRF5—systemic scleroderma	3.23e-05	0.00066	CbGpPWpGaD
Pimozide—CALM1—Immune System—IRF5—systemic scleroderma	3.23e-05	0.00066	CbGpPWpGaD
Pimozide—HTR1A—GPCR downstream signaling—EDN1—systemic scleroderma	3.2e-05	0.000653	CbGpPWpGaD
Pimozide—CALM3—Immune System—IRF8—systemic scleroderma	3.19e-05	0.000652	CbGpPWpGaD
Pimozide—CALM3—Immune System—CD247—systemic scleroderma	3.19e-05	0.000652	CbGpPWpGaD
Pimozide—CALM3—Immune System—ITGAM—systemic scleroderma	3.19e-05	0.000652	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.18e-05	0.000649	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.18e-05	0.000649	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—HSPG2—systemic scleroderma	3.17e-05	0.000647	CbGpPWpGaD
Pimozide—CALM2—Disease—HSPG2—systemic scleroderma	3.14e-05	0.000641	CbGpPWpGaD
Pimozide—CALM1—Disease—HSPG2—systemic scleroderma	3.14e-05	0.000641	CbGpPWpGaD
Pimozide—CALM3—Disease—CSK—systemic scleroderma	3.13e-05	0.00064	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—SMAD7—systemic scleroderma	3.11e-05	0.000636	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—CD40LG—systemic scleroderma	3.1e-05	0.000634	CbGpPWpGaD
Pimozide—CALM1—Immune System—ITGAM—systemic scleroderma	3.09e-05	0.000631	CbGpPWpGaD
Pimozide—CALM2—Immune System—IRF8—systemic scleroderma	3.09e-05	0.000631	CbGpPWpGaD
Pimozide—CALM1—Immune System—IRF8—systemic scleroderma	3.09e-05	0.000631	CbGpPWpGaD
Pimozide—CALM2—Immune System—ITGAM—systemic scleroderma	3.09e-05	0.000631	CbGpPWpGaD
Pimozide—CALM2—Immune System—CD247—systemic scleroderma	3.09e-05	0.000631	CbGpPWpGaD
Pimozide—CALM1—Immune System—CD247—systemic scleroderma	3.09e-05	0.000631	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—CSK—systemic scleroderma	3.06e-05	0.000625	CbGpPWpGaD
Pimozide—CALM3—Hemostasis—MMP1—systemic scleroderma	3.05e-05	0.000623	CbGpPWpGaD
Pimozide—CALM2—Disease—CSK—systemic scleroderma	3.03e-05	0.000619	CbGpPWpGaD
Pimozide—CALM1—Disease—CSK—systemic scleroderma	3.03e-05	0.000619	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—SMAD7—systemic scleroderma	3.01e-05	0.000616	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—SMAD7—systemic scleroderma	3.01e-05	0.000616	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—CD40LG—systemic scleroderma	3e-05	0.000613	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—CD40LG—systemic scleroderma	3e-05	0.000613	CbGpPWpGaD
Pimozide—CALM3—Immune System—TNFAIP3—systemic scleroderma	2.99e-05	0.000611	CbGpPWpGaD
Pimozide—CALM3—Immune System—BLK—systemic scleroderma	2.95e-05	0.000603	CbGpPWpGaD
Pimozide—CALM2—Hemostasis—MMP1—systemic scleroderma	2.95e-05	0.000603	CbGpPWpGaD
Pimozide—CALM1—Hemostasis—MMP1—systemic scleroderma	2.95e-05	0.000603	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—RHOB—systemic scleroderma	2.95e-05	0.000603	CbGpPWpGaD
Pimozide—CALM3—Disease—CD247—systemic scleroderma	2.95e-05	0.000602	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—EDN1—systemic scleroderma	2.9e-05	0.000593	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—RHOB—systemic scleroderma	2.9e-05	0.000593	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—RHOB—systemic scleroderma	2.9e-05	0.000592	CbGpPWpGaD
Pimozide—CALM2—Immune System—TNFAIP3—systemic scleroderma	2.89e-05	0.000591	CbGpPWpGaD
Pimozide—CALM1—Immune System—TNFAIP3—systemic scleroderma	2.89e-05	0.000591	CbGpPWpGaD
Pimozide—CYP3A7—Metabolism—CTGF—systemic scleroderma	2.86e-05	0.000585	CbGpPWpGaD
Pimozide—CALM1—Immune System—BLK—systemic scleroderma	2.86e-05	0.000584	CbGpPWpGaD
Pimozide—CALM2—Immune System—BLK—systemic scleroderma	2.86e-05	0.000584	CbGpPWpGaD
Pimozide—CALM2—Disease—CD247—systemic scleroderma	2.85e-05	0.000582	CbGpPWpGaD
Pimozide—CALM1—Disease—CD247—systemic scleroderma	2.85e-05	0.000582	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—RHOB—systemic scleroderma	2.85e-05	0.000582	CbGpPWpGaD
Pimozide—CALM3—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.84e-05	0.000579	CbGpPWpGaD
Pimozide—DRD2—GPCR downstream signaling—EDN1—systemic scleroderma	2.81e-05	0.000574	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.8e-05	0.000572	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—HSPG2—systemic scleroderma	2.78e-05	0.000568	CbGpPWpGaD
Pimozide—HTR2A—GPCR downstream signaling—EDN1—systemic scleroderma	2.76e-05	0.000564	CbGpPWpGaD
Pimozide—HRH1—GPCR downstream signaling—EDN1—systemic scleroderma	2.76e-05	0.000563	CbGpPWpGaD
Pimozide—CALM2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.74e-05	0.000561	CbGpPWpGaD
Pimozide—CALM1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.74e-05	0.000561	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—HSPG2—systemic scleroderma	2.74e-05	0.000559	CbGpPWpGaD
Pimozide—CYP2E1—Metabolism—HSPG2—systemic scleroderma	2.73e-05	0.000559	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—HSPG2—systemic scleroderma	2.73e-05	0.000558	CbGpPWpGaD
Pimozide—CYP3A5—Metabolism—HSPG2—systemic scleroderma	2.73e-05	0.000558	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—CCL2—systemic scleroderma	2.72e-05	0.000556	CbGpPWpGaD
Pimozide—CALM3—Metabolism—HSPG2—systemic scleroderma	2.72e-05	0.000555	CbGpPWpGaD
Pimozide—CHRM2—GPCR downstream signaling—EDN1—systemic scleroderma	2.71e-05	0.000554	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—HSPG2—systemic scleroderma	2.69e-05	0.000549	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—CSK—systemic scleroderma	2.69e-05	0.000549	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—CCL2—systemic scleroderma	2.68e-05	0.000548	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—CSK—systemic scleroderma	2.64e-05	0.00054	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—CSK—systemic scleroderma	2.64e-05	0.000539	CbGpPWpGaD
Pimozide—CALM2—Metabolism—HSPG2—systemic scleroderma	2.63e-05	0.000537	CbGpPWpGaD
Pimozide—CALM1—Metabolism—HSPG2—systemic scleroderma	2.63e-05	0.000537	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—CSK—systemic scleroderma	2.6e-05	0.00053	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—EDN1—systemic scleroderma	2.55e-05	0.000521	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—EDN1—systemic scleroderma	2.51e-05	0.000513	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—EDN1—systemic scleroderma	2.5e-05	0.000511	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—EDN1—systemic scleroderma	2.46e-05	0.000503	CbGpPWpGaD
Pimozide—CALM3—Immune System—CTLA4—systemic scleroderma	2.42e-05	0.000494	CbGpPWpGaD
Pimozide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.42e-05	0.000494	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—RHOB—systemic scleroderma	2.41e-05	0.000492	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—EDN1—systemic scleroderma	2.35e-05	0.00048	CbGpPWpGaD
Pimozide—CALM2—Immune System—CTLA4—systemic scleroderma	2.34e-05	0.000478	CbGpPWpGaD
Pimozide—CALM1—Immune System—CTLA4—systemic scleroderma	2.34e-05	0.000478	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—RHOB—systemic scleroderma	2.33e-05	0.000476	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—RHOB—systemic scleroderma	2.33e-05	0.000476	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—EDN1—systemic scleroderma	2.32e-05	0.000473	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—CCL2—systemic scleroderma	2.3e-05	0.00047	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—CCL2—systemic scleroderma	2.28e-05	0.000465	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—HSPG2—systemic scleroderma	2.27e-05	0.000464	CbGpPWpGaD
Pimozide—CALM3—Hemostasis—NOS3—systemic scleroderma	2.21e-05	0.000452	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—HSPG2—systemic scleroderma	2.2e-05	0.000449	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—HSPG2—systemic scleroderma	2.2e-05	0.000449	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—CSK—systemic scleroderma	2.19e-05	0.000448	CbGpPWpGaD
Pimozide—CALM2—Hemostasis—NOS3—systemic scleroderma	2.14e-05	0.000437	CbGpPWpGaD
Pimozide—CALM1—Hemostasis—NOS3—systemic scleroderma	2.14e-05	0.000437	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—CSK—systemic scleroderma	2.12e-05	0.000434	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—CSK—systemic scleroderma	2.12e-05	0.000434	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism—HSPG2—systemic scleroderma	2.11e-05	0.000431	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—EDN1—systemic scleroderma	2.08e-05	0.000425	CbGpPWpGaD
Pimozide—CYP2E1—Metabolism—CTGF—systemic scleroderma	2.07e-05	0.000423	CbGpPWpGaD
Pimozide—CYP3A5—Metabolism—CTGF—systemic scleroderma	2.07e-05	0.000423	CbGpPWpGaD
Pimozide—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.06e-05	0.000421	CbGpPWpGaD
Pimozide—CALM3—Metabolism—CTGF—systemic scleroderma	2.06e-05	0.000421	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—EDN1—systemic scleroderma	2.01e-05	0.000412	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—EDN1—systemic scleroderma	2.01e-05	0.000412	CbGpPWpGaD
Pimozide—CALM2—Metabolism—CTGF—systemic scleroderma	1.99e-05	0.000407	CbGpPWpGaD
Pimozide—CALM1—Metabolism—CTGF—systemic scleroderma	1.99e-05	0.000407	CbGpPWpGaD
Pimozide—CALM3—Immune System—HLA-DQB1—systemic scleroderma	1.99e-05	0.000407	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—EDN1—systemic scleroderma	1.99e-05	0.000406	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—CCL2—systemic scleroderma	1.99e-05	0.000406	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—EDN1—systemic scleroderma	1.97e-05	0.000402	CbGpPWpGaD
Pimozide—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.94e-05	0.000397	CbGpPWpGaD
Pimozide—CALM2—Immune System—HLA-DQB1—systemic scleroderma	1.93e-05	0.000394	CbGpPWpGaD
Pimozide—CALM1—Immune System—HLA-DQB1—systemic scleroderma	1.93e-05	0.000394	CbGpPWpGaD
Pimozide—CALM3—Immune System—IL1A—systemic scleroderma	1.89e-05	0.000387	CbGpPWpGaD
Pimozide—CALM3—Immune System—CD40LG—systemic scleroderma	1.88e-05	0.000384	CbGpPWpGaD
Pimozide—CALM2—Immune System—IL1A—systemic scleroderma	1.83e-05	0.000374	CbGpPWpGaD
Pimozide—CALM1—Immune System—IL1A—systemic scleroderma	1.83e-05	0.000374	CbGpPWpGaD
Pimozide—CALM1—Immune System—CD40LG—systemic scleroderma	1.82e-05	0.000372	CbGpPWpGaD
Pimozide—CALM2—Immune System—CD40LG—systemic scleroderma	1.82e-05	0.000372	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—CCL2—systemic scleroderma	1.74e-05	0.000356	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—EDN1—systemic scleroderma	1.72e-05	0.00035	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—CCL2—systemic scleroderma	1.71e-05	0.00035	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—CCL2—systemic scleroderma	1.71e-05	0.00035	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—CCL2—systemic scleroderma	1.68e-05	0.000344	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism—HSPG2—systemic scleroderma	1.64e-05	0.000336	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—CCL2—systemic scleroderma	1.61e-05	0.000328	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism—CTGF—systemic scleroderma	1.6e-05	0.000327	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—CCL2—systemic scleroderma	1.58e-05	0.000324	CbGpPWpGaD
Pimozide—ABCB1—Metabolism—CTGF—systemic scleroderma	1.56e-05	0.000319	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—EDN1—systemic scleroderma	1.51e-05	0.000308	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—EDN1—systemic scleroderma	1.48e-05	0.000303	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—EDN1—systemic scleroderma	1.48e-05	0.000302	CbGpPWpGaD
Pimozide—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.47e-05	0.0003	CbGpPWpGaD
Pimozide—CALM3—Hemostasis—TGFB1—systemic scleroderma	1.46e-05	0.000299	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—EDN1—systemic scleroderma	1.46e-05	0.000297	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—NOS3—systemic scleroderma	1.43e-05	0.000293	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—CCL2—systemic scleroderma	1.42e-05	0.000291	CbGpPWpGaD
Pimozide—CALM1—Hemostasis—TGFB1—systemic scleroderma	1.41e-05	0.000289	CbGpPWpGaD
Pimozide—CALM2—Hemostasis—TGFB1—systemic scleroderma	1.41e-05	0.000289	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—NOS3—systemic scleroderma	1.41e-05	0.000288	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—CCL2—systemic scleroderma	1.38e-05	0.000281	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—CCL2—systemic scleroderma	1.38e-05	0.000281	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—CCL2—systemic scleroderma	1.36e-05	0.000278	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—CCL2—systemic scleroderma	1.35e-05	0.000275	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.27e-05	0.000259	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism—CTGF—systemic scleroderma	1.25e-05	0.000255	CbGpPWpGaD
Pimozide—CYP3A7—Metabolism—NOS3—systemic scleroderma	1.25e-05	0.000254	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—EDN1—systemic scleroderma	1.23e-05	0.000251	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—NOS3—systemic scleroderma	1.21e-05	0.000247	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—NOS3—systemic scleroderma	1.2e-05	0.000245	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—EDN1—systemic scleroderma	1.19e-05	0.000243	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—EDN1—systemic scleroderma	1.19e-05	0.000243	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—CCL2—systemic scleroderma	1.17e-05	0.00024	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—MMP9—systemic scleroderma	1.15e-05	0.000235	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—MMP9—systemic scleroderma	1.13e-05	0.000231	CbGpPWpGaD
Pimozide—CALM3—Disease—NOS3—systemic scleroderma	1.07e-05	0.000219	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—NOS3—systemic scleroderma	1.05e-05	0.000214	CbGpPWpGaD
Pimozide—CALM2—Disease—NOS3—systemic scleroderma	1.04e-05	0.000212	CbGpPWpGaD
Pimozide—CALM1—Disease—NOS3—systemic scleroderma	1.04e-05	0.000212	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—CCL2—systemic scleroderma	1.03e-05	0.00021	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—CCL2—systemic scleroderma	1.01e-05	0.000207	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—CCL2—systemic scleroderma	1.01e-05	0.000207	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—CCL2—systemic scleroderma	9.95e-06	0.000203	CbGpPWpGaD
Pimozide—CALM3—Immune System—IL1B—systemic scleroderma	9.86e-06	0.000202	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—MMP9—systemic scleroderma	9.71e-06	0.000198	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—MMP9—systemic scleroderma	9.62e-06	0.000197	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—CTGF—systemic scleroderma	9.62e-06	0.000196	CbGpPWpGaD
Pimozide—CALM2—Immune System—IL1B—systemic scleroderma	9.54e-06	0.000195	CbGpPWpGaD
Pimozide—CALM1—Immune System—IL1B—systemic scleroderma	9.54e-06	0.000195	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—TGFB1—systemic scleroderma	9.47e-06	0.000194	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—TGFB1—systemic scleroderma	9.34e-06	0.000191	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—NOS3—systemic scleroderma	9.18e-06	0.000187	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—NOS3—systemic scleroderma	9.03e-06	0.000184	CbGpPWpGaD
Pimozide—CYP2E1—Metabolism—NOS3—systemic scleroderma	9.02e-06	0.000184	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—NOS3—systemic scleroderma	9.01e-06	0.000184	CbGpPWpGaD
Pimozide—CYP3A5—Metabolism—NOS3—systemic scleroderma	9e-06	0.000184	CbGpPWpGaD
Pimozide—CALM3—Metabolism—NOS3—systemic scleroderma	8.96e-06	0.000183	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—NOS3—systemic scleroderma	8.87e-06	0.000181	CbGpPWpGaD
Pimozide—CALM1—Metabolism—NOS3—systemic scleroderma	8.67e-06	0.000177	CbGpPWpGaD
Pimozide—CALM2—Metabolism—NOS3—systemic scleroderma	8.67e-06	0.000177	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—CCL2—systemic scleroderma	8.41e-06	0.000172	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—MMP9—systemic scleroderma	8.39e-06	0.000171	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—CCL2—systemic scleroderma	8.13e-06	0.000166	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—CCL2—systemic scleroderma	8.13e-06	0.000166	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—TGFB1—systemic scleroderma	8.01e-06	0.000164	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—TGFB1—systemic scleroderma	7.93e-06	0.000162	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—NOS3—systemic scleroderma	7.5e-06	0.000153	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—MMP9—systemic scleroderma	7.36e-06	0.00015	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—NOS3—systemic scleroderma	7.25e-06	0.000148	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—NOS3—systemic scleroderma	7.25e-06	0.000148	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—MMP9—systemic scleroderma	7.24e-06	0.000148	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—MMP9—systemic scleroderma	7.23e-06	0.000148	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—MMP9—systemic scleroderma	7.11e-06	0.000145	CbGpPWpGaD
Pimozide—CALM3—Disease—TGFB1—systemic scleroderma	7.08e-06	0.000145	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism—NOS3—systemic scleroderma	6.96e-06	0.000142	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—TGFB1—systemic scleroderma	6.91e-06	0.000141	CbGpPWpGaD
Pimozide—CALM2—Disease—TGFB1—systemic scleroderma	6.85e-06	0.00014	CbGpPWpGaD
Pimozide—CALM1—Disease—TGFB1—systemic scleroderma	6.85e-06	0.00014	CbGpPWpGaD
Pimozide—ABCB1—Metabolism—NOS3—systemic scleroderma	6.79e-06	0.000139	CbGpPWpGaD
Pimozide—CYP2D6—Metabolism—NOS3—systemic scleroderma	6.4e-06	0.000131	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—TGFB1—systemic scleroderma	6.07e-06	0.000124	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—MMP9—systemic scleroderma	6.01e-06	0.000123	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—TGFB1—systemic scleroderma	5.97e-06	0.000122	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—TGFB1—systemic scleroderma	5.96e-06	0.000122	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—TGFB1—systemic scleroderma	5.86e-06	0.00012	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—MMP9—systemic scleroderma	5.82e-06	0.000119	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—MMP9—systemic scleroderma	5.82e-06	0.000119	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism—NOS3—systemic scleroderma	5.42e-06	0.000111	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—TGFB1—systemic scleroderma	4.96e-06	0.000101	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—TGFB1—systemic scleroderma	4.79e-06	9.8e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—TGFB1—systemic scleroderma	4.79e-06	9.8e-05	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—NOS3—systemic scleroderma	4.19e-06	8.55e-05	CbGpPWpGaD
